Skip to content

Evaluation of EmBlocker*

Evaluation of EmBlocker* - NX-EM-02

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON30749
Enrollment
30
Registered
2007-07-25
Start date
2007-11-12
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebrovascular incident stroke TIA

Interventions

The EM-blocker* shall be activated at different times during the operation. These moments are mostly at times the aorta is manipulated, like during cannulation and decannulation, the insertion of th

Sponsors

Neurosonix Ltd
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 65

Exclusion criteria

Exclusion criteria: Off-pump surgery Temporal window not detected for transcranial doppler measurements Re-do procedure Emergency operation required Has a life threatening debilitating disease other than cardiac Stroke history (pre-excisting TIA and/or CVA) Patients with renal failure requiring dialysis The patient has been treated with an investigational drug or device within 30 days prior to surgery and/or will be treated peri- or post-operatively

Design outcomes

Primary

MeasureTime frame
Primary efficacy endpoint: the amount of embolic signals, registered with the TCD. Primary safety endpoint: absence of device-related serious complications.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)